Rab18 is reduced in pituitary tumors causing acromegaly and its overexpression reverts growth hormone hypersecretion

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 6, 2008, Pages 2269-2276

  Vazquez Martinez, Rafael ^a,b   Martinez Fuentes, Antonio J ^a,b   Pulido, Marina R ^a,b   Jimenez Reina, Luis ^a   Quintero, Ana ^a,b   Leal Cerro, Alfonso ^c   Soto, Alfonso ^c   Webb, Susan M ^d   Sucunza, Nuria ^d   Bartumeus, Frederic ^d   Benito Lopez, Pedro ^e   Galvez Moreno, Maria A ^e   Castaño, Justo P ^a,b   Malagon, Maria M ^a,b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; OCTREOTIDE; PEGVISOMANT; PROTEIN RAB18; RAB PROTEIN;

ACROMEGALY; ARTICLE; CELL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HORMONE RELEASE; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOELECTRON MICROSCOPY; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SECRETORY GRANULE; TRANSSPHENOIDAL SURGERY;

EID: 45149115003     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1893     Document Type: Article

References (37)

1. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
2. Daly AF, Petrossians P, Beckers A 2005 An overview of the epidemiology and genetics of acromegaly. J Endocrinol Invest 28:67-69
3. Melmed S 2006 Medical progress: Acromegaly. N Engl J Med 355:2558-2573
4. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A 2006 High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769-4775
5. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE 1979 Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 301:1138-1142
6. Swearingen B, Barker FG, 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
7. Melmed S, Jackson I, Kleinberg D, Klibanski A 1998 Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83:2646-2652
8. Holdaway IM 2004 Treatment of acromegaly. Horm Res 62(Suppl 3):79-92
9. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB 1998 Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83:3411-3418
10. Ben-Shlomo A, Melmed S 2003 Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 88:963-968
11. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D 1998 Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139:516-521
12. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-378
13. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
14. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
15. Colao A, Pivonello R, Cappabianca P, Auriemma RS, De Martino MC, Ciccarelli A, de Divitiis E, Lombardi G 2003 The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. J Endocrinol Invest 26:53-56
16. Zerial M, McBride H 2001 Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2:107-117
17. Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, Wulffraat N, Bianchi D, Fischer A, Le Deist F, de Saint Basile G 2000 Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 25:173-176
18. Seabra MC, Mules EH, Hume AN 2002 Rab GTPases, intracellular traffic and disease. Trends Mol Med 8:23-30
19. Verhoeven K, De Jonghe P, Coen K, Verpoorten N, Auer-Grumbach M, Kwon JM, FitzPatrick D, Schmedding E, De Vriendt E, Jacobs A, Van Gerwen V, Wagner K, Hartung HP, Timmerman V 2003 Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 72:722-727
20. Nachury MV, Loktev AV, Zhang Q, Westlake CJ, Peranen J, Merdes A, Slusarski DC, Scheller RH, Bazan JF, Sheffield VC, Jackson PK 2007 A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis. Cell 129:1201-1213
21. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M, Heon E, Krupin T, Ritch R, Kreutzer D, Crick RP, Sarfarazi M 2002 Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 295:1077-1079
22. Pei L, Peng Y, Yang Y, Ling XB, Van Eyndhoven WG, Nguyen KC, Rubin M, Hoey T, Powers S, Li J 2002 PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. Cancer Res 62:5420-5424
23. Croizet-Berger K, Daumerie C, Couvreur M, Courtoy PJ, van den Hove MF 2002 The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production. Proc Natl Acad Sci USA 99:8277-8282
24. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB 2004 The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10:1251-1256
25. Cheng KW, Lahad JP, Gray JW, Mills GB 2005 Emerging role of RAB GTPases in cancer and human disease. Cancer Res 65:2516-2519
26. Vazquez-Martinez R, Cruz-Garcia D, Duran-Prado M, Peinado JR, Castano JP, Malagon MM 2007 Rab18 inhibits secretory activity in neuroendocrine cells by interacting with secretory granules. Traffic 8:867-882
27. Peinado JR, Castano JP, Vazquez-Martinez R, Anouar Y, Tonon MC, Vaudry H, Gracia-Navarro F, Malagon MM 2002 Amphibian melanotrophs as a model to analyze the secretory plasticity of endocrine cells. Gen Comp Endocrinol 126:4-6
28. Martinez-Fuentes AJ, Moreno-Fernandez J, Vazquez-Martinez R, Duran-Prado M, de la Riva A, Tena-Sempere M, Dieguez C, Jimenez-Reina L, Webb SM, Pumar A, Leal-Cerro A, Benito-Lopez P, Malagon MM, Castano JP 2006 Ghrelin is produced by and directly activates corticotrope cells from adrenocorticotropin-secreting adenomas. J Clin Endocrinol Metab 91:2225-2231
29. Dobado-Berrios PM, Ruiz-Navarro A, Torronteras R, Gracia-Navarro F 1992 Application of an optimized immunostaining technique to evaluate the heterogeneous secretory response from porcine somatotropes by cell blotting. J Histochem Cytochem 40:1715-1724
30. Cochilla AJ, Angleson JK, Betz WJ 1999 Monitoring secretory membrane with FM1-43 fluorescence. Annu Rev Neurosci 22:1-10
31. Rosa P, Gerdes HH 1994 The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors. J Endocrinol Invest 17:207-225
32. Taupenot L, Harper KL, O'Connor DT 2003 The chromogranin- secretogranin family. N Engl J Med 348:1134-1149
33. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M, Faglia G 1990 Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71:1421-1426
34. Dou T, Ji C, Gu S, Chen F, Xu J, Ye X, Ying K, Xie Y, Mao Y 2005 Cloning and characterization of a novel splice variant of human Rab18 gene (RAB18)dagger. DNA Seq 16:230-234
35. Schafer U, Seibold S, Schneider A, Neugebauer E 2000 Isolation and characterisation of the human rab18 gene after stimulation of endothelial cells with histamine. FEBS Lett 466:148-154
36. Behrends U, Schneider I, Rossler S, Frauenknecht H, Golbeck A, Lechner B, Eigenstetter G, Zobywalski C, Muller-Weihrich S, Graubner U, Schmid I, Sackerer D, Spath M, Goetz C, Prantl F, Asmuss HP, Bise K, Mautner J 2003 Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries. Int J Cancer 106:244-251
37. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G 2001 Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786